RC198 / Rongchang Pharma - LARVOL DELTA

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: RemeGen Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2024 ➔ Dec 2024 | Trial primary completion date: Jun 2024 ➔ Sep 2024

Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

A Study of RC198 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: RemeGen Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

A Study of RC198 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: RemeGen Co., Ltd.

Metastases • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer